Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

ERYTECH completes patient enrollment in phase 2 trial of eryaspase for pancreatic cancer ERYTECH Pharma has enrolled final patient in its phase 2 trial of eryaspase, also known as ERY-ASP or GRASPA, for the treatment of pancreatic cancer.
Contract Research & Services > Clinical Trials > News
Teva's second phase III study of SD-809 in TD shows statistically significant results By PBR Staff Writer
A phase III clinical trial, AIM-TD, evaluating Teva Pharmaceutical Industries' SD-809 (deutetrabenazine) to treat tardive dyskinesia (TD) demonstrated a statistically valid treatment benefit.
Contract Research & Services > Clinical Trials > News AstraZeneca diabetes drug combination meets main goals in Phase III study By PBR Staff Writer
AstraZeneca said a combination of two diabetes medications significantly lowered blood sugar, weight and blood pressure in a Phase III trial.
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
AstraZeneca diabetes drug combination meets main goals in Phase III study
By PBR Staff Writer
AstraZeneca said a combination of two diabetes medications significantly lowered blood sugar, weight and blood pressure in a Phase III trial.
Contract Research & Services > Clinical Trials > News
Novavax’s respiratory disease vaccine fails in phase 3 trial
By PBR Staff Writer
Novavax’s RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) has failed to meet pre-specified efficacy objectives in a phase 3 trial in older adults.
Contract Research & Services > Clinical Trials > News
Xencor starts phase 1b trial of subcutaneous formulation of XmAb7195
Xencor has dosed the first patient in a Phase 1b multi-dose trial of subcutaneously administered XmAb7195, a potential treatment for allergic disease.
Contract Research & Services > Clinical Trials > News
Merck and Pfizer's diabetes treatment meets primary endpoint in phase 3 trial
By PBR Staff Writer
Merck and Pfizer announced that ertugliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor they are developing together, demonstrated significantly greater reductions in glycated hemoglobin (A1C) compared with placebo.
Contract Research & Services > Clinical Trials > News
GSK’s shingles vaccine remains effective after four years in phase III study
By PBR Staff Writer
GlaxoSmithKline’s (GSK) experimental shingles vaccine remained effective for about four years in a phase III study in people aged 70 and older.
Contract Research & Services > Clinical Trials > News
Aerie Pharmaceuticals' eye drug meets main goal in phase 3 trial
Aerie Pharmaceuticals has reported the successful 90-day primary efficacy results of its 12-month Phase 3 Mercury 1 clinical trial for its fixed-dose combination product candidate, Roclatan.
Contract Research & Services > Clinical Trials > News
AstraZeneca launches two new phase IIIb trials for Forxiga
AstraZeneca announced two new randomised, placebo-controlled Phase IIIb outcome trials with Forxiga (dapagliflozin), an SGLT-2 inhibitor currently indicated for the treatment of type-2 diabetes.
Contract Research & Services > Clinical Trials > News
Foamix’s FMX103 meets efficacy endpoints in phase 2 trial for papulopustular rosacea
By PBR Staff Writer
A phase 2 clinical trial evaluating Foamix Pharmaceuticals' FMX103 to treat moderate-to-severe papulopustular rosacea (PR) demonstrated statistically significant improvement compared with vehicle in the main efficacy endpoints.
Contract Research & Services > Clinical Trials > News
Xencor doses first patient in phase 1 clinical trial of XmAb14045
Xencor has dosed the first patient in a Phase 1 clinical trial of XmAb14045 for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies.
Contract Research & Services > Clinical Trials > News
GTx achieves stage 1 milestone in phase 2 trial of enobosarm in ER+/AR+ breast cancer
GTx has achieved the Stage 1 milestone for the 9 mg cohort of its Phase 2 clinical trial of enobosarm (GTx-024) to treat women with advanced, estrogen receptor positive (ER+), androgen receptor positive (AR+) breast cancer.
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests